Mid-size pharmaceutical companies operate in one of the most complex environments in healthcare.
They pursue innovative therapies with the agility of smaller organisations yet face the same regulatory expectations, documentation standards and inspection scrutiny as global pharmaceutical giants.
These organisations must navigate the complex path of ambitious growth strategies supported by limited infrastructure and expanding pipelines while meeting regulators’ requests for transparency.
Check out the rest of the feature here
